How much does a box of Pemetinib cost in China?

Pemetinib (pemetinib) is an innovative targeted therapy specifically targeting advanced cholangiocarcinoma and relapsed or refractory myeloid and lymphoid tumors. It effectively controls tumor growth and spread by precisely inhibiting the activity of fibroblast growth factor receptors (especially FGFR2 and FGFR1).

In clinical trials, pemetinib has shown significant efficacy in cholangiocarcinoma, especially for patients with advanced, metastatic or unresectable cholangiocarcinoma withFGFR2 fusion or rearrangement. The objective response rate can reach approximately 35.5%, and the disease control rate can reach as high as 82%. This means that pemetinib is effective in stabilizing or slowing the progression of the disease. Additionally, the drug's median duration of response was 9.1 months, demonstrating its ability to control the disease over the long term. For many patients, pemetinib not only extends survival but also improves quality of life. However, as a powerful drug, it is necessary to strictly follow medical instructions when using it to ensure safety and effectiveness. The advent of pemetinib undoubtedly provides a new and powerful weapon for the treatment of difficult diseases such as cholangiocarcinoma.

Pemetinib has been on the market in China for a long time, and patients can purchase it directly from domestic hospitals. The specifications of the domestic original research version are 4.5 mg and 14 tablets, and the price is about 30,000 yuan. It is reported that there are both original and generic versions abroad. The original version of 13.5 mg 14 tablets costs about 72,000 yuan; while the generic version of Lucius Pharmaceuticals in Laos, 4.5 mg*14 tablets, only costs about 850 yuan. For inquiries about pemetinib, please contact a regular overseas medical company.

In summary, pemetinib, with its unique molecular mechanism and excellent therapeutic effect, brings hope to patients with advanced cancer, especially those with cholangiocarcinoma. Its remarkable efficacy and disease control rate make pemetinib a key drug in the current field of cancer treatment.